The EMA Grants Orphan Drug Designation to Neurenatis NEU001 for the Treatment of Hirschsprung Disease

Image for article The EMA Grants Orphan Drug Designation to Neurenatis NEU001 for the Treatment of Hirschsprung Disease
News Source : Financial Post

News Summary

  • Neurenati Therapeutics Inc. is a biotechnology company dedicated to developing transformative therapies for rare pediatric diseases.
  • Its lead program focuses on Hirschsprung disease (HD), a life-threatening congenital gastrointestinal (GI) disorder caused by the absence of nerve cells in parts of the lower GI tract.
  • Neurenati’s IND-enabling preclinical program for NEU-001 is currently underway, with plans to initiate a first-in-human clinical trial by the end of 2026.
MONTREAL Neurenati Therapeutics Inc., a biotechnology company dedicated to developing transformative therapies for rare pediatric diseases, is pleased to announce that the European Medicines Agency ( [+4823 chars]

Must read Articles